Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
157 studies found for:    Spinal Muscular Atrophy
Show Display Options
Rank Status Study
21 Completed An Open-label Safety, Tolerability, and Dose-range Finding Study of ISIS SMNRx in Patients With Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Intervention: Drug: ISIS-SMNRx
22 Active, not recruiting A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Infants With Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Interventions: Drug: IONIS-SMN Rx;   Procedure: Sham procedure
23 Active, not recruiting A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Patients With Later-onset Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Interventions: Drug: IONIS-SMN Rx;   Procedure: Sham procedure
24 Completed An Open-label Safety and Tolerability Study of ISIS SMNRx in Patients With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1
Condition: Spinal Muscular Atrophy
Intervention: Drug: ISIS-SMNRx
25 Completed An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Intervention: Drug: ISIS-SMNRx
26 Active, not recruiting A Study to Assess the Efficacy, Safety and Pharmacokinetics of IONIS SMNRx in Infants With Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Intervention: Drug: IONIS-SMNRx
27 Completed Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Intervention: Drug: Valproic Acid
28 Completed Aerobic Training in Patients With Spinal Muscular Atrophy Type III
Condition: Spinal Muscular Atrophy
Intervention: Behavioral: Aerobic conditioning
29 Active, not recruiting An Open-label Safety and Tolerability Study of IONIS SMNRx in Patients With Spinal Muscular Atrophy Who Previously Participated in IONIS SMNRx-CS2 or IONIS SMNRx-CS10
Condition: Spinal Muscular Atrophy
Intervention: Drug: IONIS-SMNRx
30 Recruiting A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Interventions: Drug: CK-2127107 150 mg;   Drug: Placebo;   Drug: CK-2127107 450 mg
31 Recruiting A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Intervention: Drug: Nusinersen
32 Completed A Trial of Hydroxyurea in Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Intervention: Drug: Hydroxyurea
33 Available Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Condition: Infantile-onset Spinal Muscular Atrophy (SMA)
Intervention: Drug: nusinersen
34 Active, not recruiting Palliative Care in Spinal Muscular Atrophy (SMA) 1
Condition: Spinal Muscular Atrophy 1
Intervention: Other: Follow-up diary and questionnaire
35 Recruiting Valproate and Levocarnitine in Children With Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Interventions: Drug: Valproate, Levocarnitine;   Drug: Placebo
36 Completed Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)
Conditions: Spinal Muscular Atrophy;   Neuromuscular Disease
Intervention: Other: Exercise
37 Active, not recruiting
Has Results
Progressive Strength Training in Spinal Muscular Atrophy
Condition: Muscular Atrophy, Spinal
Intervention: Other: Progressive strength training
38 Completed Evaluation of the Muscle Strength and Motor Ability in Children With Spinal Muscle Atrophy(SMA) Treated With Valproic Acid
Condition: Spinal Muscular Atrophy
Intervention:
39 Active, not recruiting A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).
Condition: Spinal Muscular Atrophy
Interventions: Drug: Nusinersen;   Procedure: Sham Procedure
40 Recruiting Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3
Condition: Spinal Muscular Atrophy Type 3
Intervention: Drug: Pyridostigmine Bromide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.